2.Clinical analysis of childhood acute generalized exanthematous pustulosis.
Jiang-Lin ZHANG ; Xiang CHEN ; Ji LI ; Hong-Fu XIE
Chinese Journal of Contemporary Pediatrics 2008;10(4):497-499
OBJECTIVETo describe the etiology, clinical features and treatment of childhood acute generalized exanthematous pustulosis (AGEP).
METHODSClinical data from 20 cases of childhood acute generalized exanthematous pustulosis from 1990 to 2008 were retrospectively reviewed.
RESULTSEighteen cases had a history of medication, including the use of penicillin (n=6), cephalosporins (n=3), sulphonamides (n=2), algopyrin (n=2), vaccines (n=2 ) and anti-cold drugs (n=3). Fever and generalized erythematous pustules were observed in all 20 cases. Histopathologic examination revealed spongiform superficial pustules and papillary edema. The patients were asked to stop taking suspected sensitizing drugs and received glucocorticoid treatment (1-2 mg/kg daily). After 3-5 days of the treatment, symptoms were improved and the dosage of glucocorticoid was gradually reduced. All patients were healed within 20 days after treatment.
CONCLUSIONSThe cause of AGEP is mainly attributed to the use of antibiotics, sulphonamides, antipyretic analgesics and vaccines in children. AGEP is characterized by fever and widespread pustular eruption of the skin. Removal of sensitizing factors and glucocorticoid administration is important in the treatment of AGEP in children.
Child ; Child, Preschool ; Drug Eruptions ; diagnosis ; etiology ; therapy ; Exanthema ; diagnosis ; etiology ; therapy ; Female ; Humans ; Male ; Prognosis ; Retrospective Studies ; Skin Diseases, Vesiculobullous ; diagnosis ; etiology ; therapy
3.Impact of COVID-19 on Clinical Operations and Management of Patients in a Singapore Immunodermatology Unit during the 'Circuit-Breaker' Period and Beyond.
Annals of the Academy of Medicine, Singapore 2020;49(11):919-921
Allergy and Immunology
;
Ambulatory Care
;
Autoimmune Diseases/therapy*
;
COVID-19
;
Communicable Disease Control
;
Connective Tissue Diseases/therapy*
;
Delivery of Health Care/methods*
;
Dermatology
;
Humans
;
Immunosuppressive Agents/therapeutic use*
;
Patient Selection
;
SARS-CoV-2
;
Singapore
;
Skin Diseases, Vesiculobullous/therapy*
;
Telemedicine/methods*
;
Tertiary Care Centers
;
Vasculitis/therapy*